PMID- 30200146
OWN - NLM
STAT- MEDLINE
DCOM- 20181001
LR  - 20230928
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 36
DP  - 2018 Sep
TI  - The role of fluorescence in situ hybridization to predict patient response to 
      intravesical Bacillus Calmette-Guerin therapy for bladder cancer: A diagnostic 
      meta-analysis and systematic review.
PG  - e12227
LID - 10.1097/MD.0000000000012227 [doi]
LID - e12227
AB  - BACKGROUND: The aim of the study was to systematically review the relevant 
      studies to assess the role of fluorescence in situ hybridization (FISH) test for 
      predicting patient response to Bacillus Calmette-Guerin (BCG) therapy after 
      transurethral resection of bladder tumor (TURBT). METHODS: We searched PubMed, 
      Embase, and the Cochrane Library from inception to July 5, 2018, and used Quality 
      Assessment Tool for Diagnosis Accuracy Studies (QUADAS-2) to assess the quality. 
      We pooled sensitivity, specificity, and area under curve (AUC) of baseline and 
      post-BCG FISH test for predicting tumor recurrence. Hazard ratio (HR) with 95% 
      confidence intervals (95% CIs) and a Fagan nomogram were applied to assess 
      predictive accuracy of post-BCG FISH test. RESULTS: A total of 6 studies with 442 
      participants for post-BCG test and 404 participants for baseline BCG test were 
      included. The pooled analysis for post-BCG FISH test revealed the sensitivity of 
      0.54 (95% CI 0.38-0.69), specificity of 0.84 (95% CI: 0.72-0.91), and area under 
      the curve (AUC) of 0.78 (95% CI: 0.74-0.81) for predicting tumor recurrence. 
      Patients with positive post-BCG FISH test were more likely to recur during 
      follow-up (HR 3.95, 95% CI 2.72-5.72). The Fagan nomogram revealed the 
      "post-test" probability of tumor recurrence increased by 29% for patients with 
      positive post-BCG FISH test. The baseline FISH test had a pooled sensitivity of 
      0.70 (95% CI 0.55-0.81), specificity of 0.41 (95% CI: 0.26-0.58), and AUC of 0.60 
      (95% CI: 0.56-0.64) for predicting recurrence. CONCLUSION: The post-BCG FISH test 
      can predict BCG failure with high specificity and patients with positive post-BCG 
      FISH test were more likely to recur. However, the relatively low sensitivity of 
      post-BCG FISH test and unsatisfactory performance of baseline FISH test may limit 
      their mono-use.
FAU - Bao, Yige
AU  - Bao Y
AD  - Department of Urology, Institute of Urology West China School of Clinical 
      Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P.R. 
      China.
FAU - Tu, Xiang
AU  - Tu X
FAU - Chang, Tiancong
AU  - Chang T
FAU - Qiu, Shi
AU  - Qiu S
FAU - Yang, Lu
AU  - Yang L
FAU - Geng, Jiwen
AU  - Geng J
FAU - Quan, Liuliu
AU  - Quan L
FAU - Wei, Qiang
AU  - Wei Q
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (BCG Vaccine)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - BCG Vaccine/*therapeutic use
MH  - Cancer Vaccines/*therapeutic use
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Prognosis
MH  - Urinary Bladder Neoplasms/*pathology/surgery/*therapy
PMC - PMC6133599
COIS- The authors of this work have nothing to disclose and the authors report no 
      conflicts of interest.
EDAT- 2018/09/12 06:00
MHDA- 2018/10/03 06:00
PMCR- 2018/09/07
CRDT- 2018/09/12 06:00
PHST- 2018/09/12 06:00 [entrez]
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/09/07 00:00 [pmc-release]
AID - 00005792-201809070-00088 [pii]
AID - MD-D-18-03272 [pii]
AID - 10.1097/MD.0000000000012227 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Sep;97(36):e12227. doi: 10.1097/MD.0000000000012227.